Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
Open Access
- 20 October 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2), e001391
- https://doi.org/10.1136/jitc-2020-001391
Abstract
Background For small cell lung cancer (SCLC) therapy, immunotherapy might have unique advantages to some extent. Galectin-9 (Gal-9) plays an important role in antitumor immunity, while little is known of its function in SCLC. Materials and methods By mean of immunohistochemistry (IHC), we tested the expression level of Gal-9 and other immune markers on both tumor cells and tumor-infiltrating lymphocytes (TILs) in 102 surgical-resected early stage SCLC clinical samples. On the basis of statistical analysis and machine learning results, the Gal-9-based immune risk score model was constructed and its predictive performance was evaluated. Then, we thoroughly explored the effects of Gal-9 and immune risk score on SCLC immune microenvironment and immune infiltration in different cohorts and platforms. Results In the SCLC cohort for IHC, the expression level of Gal-9 on TILs was statistically correlated with the levels of program death-1 (p=0.001), program death-ligand 1 (PD-L1) (pConclusions Gal-9 is markedly related to tumor-immune microenvironment and immune infiltration in SCLC. This study emphasized the predictive value and promising clinical applications of Gal-9 in stage I–III SCLC.This publication has 69 references indexed in Scilit:
- Galectin-9 Functionally Impairs Natural Killer Cells in Humans and MiceJournal of Virology, 2013
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced DiseaseCancer Research, 2013
- The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma CellsJournal of Investigative Dermatology, 2012
- Galectin-9 signaling prolongs survival in murine lung-cancer by inducing macrophages to differentiate into plasmacytoid dendritic cell-like macrophagesClinical Immunology, 2012
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood, 2011
- Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8+ T Cell ResponsePLoS Pathogens, 2010
- Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment ParadigmsThe Oncologist, 2010
- The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial CellsThe American Journal of Pathology, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003